Olivier Varenne, MD

Radial Versus Femoral Approach for Percutaneous Coronary Intervention: MACE Outcomes at Long-Term Follow-up

06/27/2018

Francisco Campelo-Parada , MD;

Atsuo Namiki , MD;

Antonio Serra-Peñaranda , MD;

Olivier Varenne , MD;

William Wijns , MD, PhD;

Kazushige Kadota , MD;

Didier Carrié , MD, PhD;

Tetsuya Tobaru , MD;

Antonio L. Bartorelli , MD;

Thomas Hovasse , MD;

Kenshi Fujii , MD;

Shigeru Nakamura , MD;

Takeshi Kimura , MD;

Jacques Lalmand , MD;

Shigeru Saito , MD;

Yuji Ikari , MD, PhD, FACC, FESC;

Little is known about the long-term major cardiovascular events and bleeding complications of patients undergoing percutaneous coronary intervention with radial vs femoral approach. Our objective was to compare the main outcomes of radial...

Little is known about the...

06/27/2018

Journal of Invasive Cardiology

Original Contribution

Clinical Outcomes in Patients Treated With Biodegradable-Polymer Biolimus-Eluting Stents and 6 Months of Dual-Antiplatelet Therapy: The French eBiomatrix 6-Month DAPT Registry

05/01/2022

Antoine Gommeaux , MD;

Vincent Malquarti , MD;

Denis Angoulvant , MD;

Clauset Cruchon , MD;

Keith G. Oldroyd , MD, MBChB, FRCP;

Christian Spaulding , MD;

Hakim Benamer , MD;

Thierry Lefèvre , MD;

Olivier Varenne , MD;

Janusz Lipiecki , MD;

Rajiv Rampat , MD;

Christophe Piot , MD;

François Brunelle , MD;

Rami el Mahmoud , MD;

Dual-antiplatelet treatment (DAPT) has conventionally been prescribed for 1 year after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation. Recent evidence suggests that a duration of only 6 months may be...

Dual-antiplatelet treatment...

05/01/2022

Journal of Invasive Cardiology